Cargando…
Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers
In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set for receptor mRNA overexpression using functional...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297821/ https://www.ncbi.nlm.nih.gov/pubmed/31478179 http://dx.doi.org/10.1007/s12253-019-00734-w |
_version_ | 1783547088587456512 |
---|---|
author | Peters, Marloes A. M. Meijer, Coby Fehrmann, Rudolf S. N. Walenkamp, Annemiek M. E. Kema, Ido P. de Vries, Elisabeth G. E. Hollema, Harry Oosting, Sjoukje F. |
author_facet | Peters, Marloes A. M. Meijer, Coby Fehrmann, Rudolf S. N. Walenkamp, Annemiek M. E. Kema, Ido P. de Vries, Elisabeth G. E. Hollema, Harry Oosting, Sjoukje F. |
author_sort | Peters, Marloes A. M. |
collection | PubMed |
description | In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set for receptor mRNA overexpression using functional genomic mRNA (FGmRNA) profiling, and we analysed protein expression and location of 5-HTR1B, 5-HTR2B, DRD1, and DRD2 with immunohistochemistry in different tumour types. With FGmRNA profiling 11,756 samples representing 43 tumour types were compared to 3,520 normal tissue samples to analyse receptor overexpression. 5-HTR2B overexpression was present in many tumour types, most frequently in uveal melanomas (56%). Receptor overexpression in rare cancers included 5-HTR1B in nasopharyngeal carcinoma (17%), DRD1 in ependymoma (30%) and synovial sarcoma (21%), and DRD2 in astrocytoma (13%). Immunohistochemistry demonstrated high 5-HTR2B protein expression on melanoma and gastro-intestinal stromal tumour cells and endothelial cells of colon, ovarian, breast, renal and pancreatic tumours. 5-HTR1B expression was predominantly low. High DRD2 protein expression on tumour cells was observed in 48% of pheochromocytomas, and DRD1 expression ranged from 14% in melanoma to 57% in renal cell carcinoma. In conclusion, 5-HTR1B, 5-HTR2B, DRD1, and DRD2 show mRNA overexpression in a broad spectrum of common and rare cancers. 5-HTR2B protein is frequently highly expressed in human cancers, especially on endothelial cells. These findings support further investigation of especially 5HTR2B as a potential treatment target. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12253-019-00734-w) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7297821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-72978212020-06-19 Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers Peters, Marloes A. M. Meijer, Coby Fehrmann, Rudolf S. N. Walenkamp, Annemiek M. E. Kema, Ido P. de Vries, Elisabeth G. E. Hollema, Harry Oosting, Sjoukje F. Pathol Oncol Res Original Article In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set for receptor mRNA overexpression using functional genomic mRNA (FGmRNA) profiling, and we analysed protein expression and location of 5-HTR1B, 5-HTR2B, DRD1, and DRD2 with immunohistochemistry in different tumour types. With FGmRNA profiling 11,756 samples representing 43 tumour types were compared to 3,520 normal tissue samples to analyse receptor overexpression. 5-HTR2B overexpression was present in many tumour types, most frequently in uveal melanomas (56%). Receptor overexpression in rare cancers included 5-HTR1B in nasopharyngeal carcinoma (17%), DRD1 in ependymoma (30%) and synovial sarcoma (21%), and DRD2 in astrocytoma (13%). Immunohistochemistry demonstrated high 5-HTR2B protein expression on melanoma and gastro-intestinal stromal tumour cells and endothelial cells of colon, ovarian, breast, renal and pancreatic tumours. 5-HTR1B expression was predominantly low. High DRD2 protein expression on tumour cells was observed in 48% of pheochromocytomas, and DRD1 expression ranged from 14% in melanoma to 57% in renal cell carcinoma. In conclusion, 5-HTR1B, 5-HTR2B, DRD1, and DRD2 show mRNA overexpression in a broad spectrum of common and rare cancers. 5-HTR2B protein is frequently highly expressed in human cancers, especially on endothelial cells. These findings support further investigation of especially 5HTR2B as a potential treatment target. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12253-019-00734-w) contains supplementary material, which is available to authorized users. Springer Netherlands 2019-09-02 2020 /pmc/articles/PMC7297821/ /pubmed/31478179 http://dx.doi.org/10.1007/s12253-019-00734-w Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Peters, Marloes A. M. Meijer, Coby Fehrmann, Rudolf S. N. Walenkamp, Annemiek M. E. Kema, Ido P. de Vries, Elisabeth G. E. Hollema, Harry Oosting, Sjoukje F. Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers |
title | Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers |
title_full | Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers |
title_fullStr | Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers |
title_full_unstemmed | Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers |
title_short | Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers |
title_sort | serotonin and dopamine receptor expression in solid tumours including rare cancers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297821/ https://www.ncbi.nlm.nih.gov/pubmed/31478179 http://dx.doi.org/10.1007/s12253-019-00734-w |
work_keys_str_mv | AT petersmarloesam serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT meijercoby serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT fehrmannrudolfsn serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT walenkampannemiekme serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT kemaidop serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT devrieselisabethge serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT hollemaharry serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers AT oostingsjoukjef serotoninanddopaminereceptorexpressioninsolidtumoursincludingrarecancers |